北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase
作者: Jiang, Hao; Chen, Shan-Shan; Jiang, Bin; Jiang, Qian; Qin, Ya-Zhen; Lai, Yue-Yun; Huang, Xiao-Jun
关键词: Chronic myeloid leukemia ; Imatinib ; Cytogenetic response ; Molecular response ; Event-free survival
刊名: ANNALS OF HEMATOLOGY
发表日期: 2011
DOI: 10.1007/s00277-010-1031-0
卷: 90, 期:1, 页:41-46
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
关键词[WOS]: CHRONIC MYELOID-LEUKEMIA ; ABL TYROSINE KINASE ; CYTOGENETIC RESPONSES ; FOLLOW-UP ; INTERFERON ; ALPHA ; CML ; INHIBITOR ; SURVIVAL ; MESYLATE
英文摘要:

The purpose of our study is to compare the 7-year response to imatinib monotherapy as an initial treatment and re-treatment in Chinese patients with chronic myelogenous leukemia-chronic phase (CML-CP) patients in a single center in Beijing. A retrospective study of 171 CML-CP patients receiving imatinib monotherapy was done with 73 in the initial treatment group (disease course a parts per thousand currency sign6 months) and 98 in the re-treatment group (disease course > 6 months). Cumulative rates of complete cytogenetic response (CCyR) at 6, 12, and 36 months after imatinib treatment in the initial and re-treatment groups were 75%, 89%, and 96%, and 48%, 77% and 84% (p = 0.0002), respectively. The median time to CCyR in the initial and re-treatment groups was 6 months (95% CI, 3.3-8.3) and 9 months (95% CI, 6.4-11.6), respectively (p = 0.0002). Cumulative rates of major molecular responses at 9, 12, and 18 months after imatinib treatment in the initial and re-treatment groups were 31%, 48%, and 60%, and 15%, 25% and 37% (p = 0.017), respectively. The median time to the major molecular response in the initial and re-treatment groups was 15 months (95% CI, 12.3-17.7) and 36 months (95% CI, 25.9-46.0), respectively (p = 0.017). Progression-free survival at 84 months in the initial and re-treatment groups was 97% and 85%, respectively (p = 0.09). Event-free survival at 84 months in the initial and re-treatment groups was 92% and 70%, respectively (p = 0.049). Only two of the 171 patients discontinued imatinib therapy for grade 3/4 adverse events. Our study revealed that CML-CP patients would benefit from early treatment with imatinib.

语种: 英语
所属项目编号: IRT 0702
项目资助者: program for innovative research team in the university
WOS记录号: WOS:000285783800007
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/67433
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China

Recommended Citation:
Jiang, Hao,Chen, Shan-Shan,Jiang, Bin,et al. Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase[J]. ANNALS OF HEMATOLOGY,2011,90(1):41-46.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jiang, Hao]'s Articles
[Chen, Shan-Shan]'s Articles
[Jiang, Bin]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jiang, Hao]‘s Articles
[Chen, Shan-Shan]‘s Articles
[Jiang, Bin]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace